Inhaled Nitric Oxide (iNO): Clinical Use in Respiratory Care

Inhaled nitric oxide (iNO) is a specialized therapeutic gas used in modern respiratory care, particularly in neonatal and pediatric critical care settings. It plays a key role in managing conditions associated with elevated pulmonary vascular resistance and impaired oxygenation.

By acting as a selective pulmonary vasodilator, iNO improves blood flow to well-ventilated regions of the lungs without causing systemic hypotension. This targeted effect makes it especially valuable in treating hypoxemic respiratory failure, most notably persistent pulmonary hypertension of the newborn.

Understanding its mechanism, indications, and clinical application is essential for respiratory therapy practice.

What Is Inhaled Nitric Oxide?

Inhaled nitric oxide (iNO) is a medical gas used in respiratory care as a selective pulmonary vasodilator. It is delivered directly into the lungs through a ventilator or other respiratory support system to improve oxygenation in patients with certain types of respiratory failure. Once inhaled, nitric oxide diffuses into the pulmonary blood vessels and relaxes smooth muscle, which lowers pulmonary vascular resistance and increases blood flow to well-ventilated areas of the lungs.

This targeted effect helps improve ventilation-perfusion matching and reduces intrapulmonary shunting, leading to better oxygen levels in the blood. iNO is most commonly used in term and near-term infants with persistent pulmonary hypertension of the newborn, a condition where the lungs fail to adapt after birth. Because it is rapidly inactivated by hemoglobin, its effects remain localized to the lungs, minimizing systemic side effects.

Overview and Clinical Significance

Inhaled nitric oxide is an advanced modality designed to address abnormalities in pulmonary circulation. It is most commonly used in term and near-term neonates with hypoxic respiratory failure related to elevated pulmonary vascular resistance. In these patients, the pulmonary vasculature fails to transition appropriately after birth, resulting in impaired oxygenation and right-to-left shunting.

The clinical value of iNO lies in its ability to improve oxygenation without significantly affecting systemic vascular tone. Unlike systemic vasodilators, which can lower blood pressure throughout the body, iNO remains localized to the pulmonary circulation. This allows clinicians to target pulmonary hypertension while maintaining stable systemic hemodynamics.

In neonatal intensive care units, iNO is often used as an early intervention to reduce the severity of hypoxemia and decrease the need for more invasive therapies such as extracorporeal membrane oxygenation. Its rapid onset of action and relative safety profile contribute to its widespread use in carefully selected patients.

Mechanism of Action

The therapeutic effects of inhaled nitric oxide are based on its ability to relax vascular smooth muscle within the pulmonary circulation. When delivered via inhalation, nitric oxide travels to the alveoli and diffuses across the alveolar-capillary membrane into adjacent pulmonary vessels.

Once inside the vascular smooth muscle cells, nitric oxide activates the enzyme guanylate cyclase. This activation increases the production of cyclic guanosine monophosphate, a second messenger that promotes smooth muscle relaxation. The result is vasodilation of pulmonary arteries, leading to reduced pulmonary vascular resistance.

NO → guanylate cyclase → cGMP ↑ → smooth muscle relaxation

A defining feature of iNO is its rapid inactivation upon entering the bloodstream. Nitric oxide binds to hemoglobin and is converted into inactive metabolites such as nitrates and methemoglobin. This rapid binding prevents systemic distribution and limits its effects to the pulmonary vasculature. As a result, systemic blood pressure remains largely unaffected.

Another important aspect of its mechanism is its selective action in ventilated lung regions. Because nitric oxide is delivered with inhaled gas, it preferentially reaches alveoli that are well ventilated. This enhances blood flow to these areas, improving ventilation-perfusion matching and reducing intrapulmonary shunting.

Effects on Ventilation-Perfusion Matching

One of the most important physiological benefits of inhaled nitric oxide is its ability to improve ventilation-perfusion relationships within the lungs. In many forms of hypoxemic respiratory failure, mismatched ventilation and perfusion contribute significantly to impaired oxygenation.

iNO enhances perfusion to well-ventilated alveoli while having little effect on poorly ventilated or collapsed regions. This redistribution of pulmonary blood flow helps reduce shunting and increases the efficiency of gas exchange. As a result, arterial oxygen levels improve without requiring excessive increases in oxygen concentration or ventilator support.

This effect is particularly beneficial in conditions such as persistent pulmonary hypertension of the newborn, where right-to-left shunting bypasses the lungs. By lowering pulmonary vascular resistance, iNO encourages blood flow through the pulmonary capillaries, allowing for improved oxygen uptake.

Indications for Use

Neonatal Indications

The primary and most well-established indication for inhaled nitric oxide is persistent pulmonary hypertension of the newborn. This condition occurs when the pulmonary circulation fails to adapt after birth, resulting in sustained high resistance and reduced pulmonary blood flow.

In affected neonates, blood bypasses the lungs through fetal circulatory pathways such as the foramen ovale and ductus arteriosus. This leads to severe hypoxemia that can be difficult to manage with conventional oxygen therapy alone.

iNO is typically initiated in term or near-term infants with evidence of pulmonary hypertension and hypoxic respiratory failure. Clinical indicators may include a high oxygenation index, significant differences between preductal and postductal oxygen saturation, or echocardiographic confirmation of elevated pulmonary pressures.

Pediatric and Other Uses

Although its primary role is in neonatal care, inhaled nitric oxide has been studied in a variety of other clinical settings. These include pediatric patients with acute respiratory distress syndrome, pulmonary hypertension following cardiac surgery, and congenital diaphragmatic hernia.

In these populations, iNO may provide short-term improvement in oxygenation by enhancing pulmonary blood flow and reducing vascular resistance. However, its impact on long-term outcomes such as survival remains uncertain in many of these conditions.

In adult patients, inhaled nitric oxide has been explored for use in acute respiratory distress syndrome and other causes of hypoxemic respiratory failure. While improvements in oxygenation are often observed, studies have not consistently demonstrated a reduction in mortality. As a result, its use in adults is generally limited and not approved for routine clinical practice.

Diagnostic Applications

In some cases, inhaled nitric oxide is used as a diagnostic tool to evaluate pulmonary vascular responsiveness. By observing changes in pulmonary pressures and oxygenation following administration, clinicians can assess the reversibility of pulmonary hypertension and guide treatment decisions.

Dosage and Administration

The administration of inhaled nitric oxide requires careful attention to dosing and delivery methods. The most common starting dose in neonatal practice is 20 parts per million. At this level, many patients experience significant improvement in oxygenation without a substantial increase in adverse effects.

Lower doses may be used in certain cases, particularly during weaning or when minimizing exposure is desired. Higher doses are generally avoided, as they do not typically provide additional clinical benefit and may increase the risk of toxicity.

iNO is delivered through specialized systems that integrate with mechanical ventilators. These systems ensure precise blending of nitric oxide with the inspired gas mixture and maintain consistent concentrations throughout the respiratory cycle.

Alternative delivery methods include continuous positive airway pressure systems and nasal cannula interfaces. However, mechanical ventilation remains the most common approach in critically ill patients due to its ability to provide controlled and consistent gas delivery.

Accurate dosing depends on continuous monitoring of nitric oxide concentrations within the inspiratory limb of the ventilator circuit. This ensures that the patient receives the intended dose while minimizing exposure to potentially harmful byproducts.

Equipment and Delivery Systems

The safe administration of inhaled nitric oxide depends on specialized equipment designed to deliver and monitor the gas accurately. These systems typically include a nitric oxide source, a delivery module, and monitoring devices for both nitric oxide and nitrogen dioxide concentrations.

The delivery system must be capable of precisely blending nitric oxide with oxygen and maintaining stable concentrations despite changes in ventilator settings. Any fluctuations in flow or pressure can affect the delivered dose, making reliable equipment essential.

Gas analyzers play a critical role in ensuring safety. Continuous measurement of nitric oxide and nitrogen dioxide levels allows clinicians to detect deviations from target concentrations and respond promptly. Oxygen analyzers are also used to monitor the fraction of inspired oxygen and maintain appropriate oxygenation levels.

Alarm systems are integrated into these devices to alert clinicians to unsafe conditions, such as elevated nitrogen dioxide levels or interruptions in nitric oxide delivery. Proper calibration and maintenance of the equipment are necessary to ensure accurate performance and patient safety.

Monitoring During Therapy

Close monitoring is essential during inhaled nitric oxide therapy to ensure both effectiveness and safety. Clinicians must continuously assess the patient’s response and adjust therapy as needed.

Key parameters that require monitoring include oxygenation status, ventilator settings, and gas concentrations. Improvements in oxygenation are often evaluated using arterial blood gas measurements or oxygenation indices. These metrics help determine whether the patient is responding appropriately to therapy.

In addition to clinical response, monitoring for potential complications is critical. Nitric oxide levels must be maintained within the prescribed range, while nitrogen dioxide levels should be kept as low as possible to prevent toxicity.

Methemoglobin levels are also monitored regularly. Because nitric oxide can oxidize hemoglobin, elevated methemoglobin levels may impair oxygen delivery. Early detection allows for prompt intervention and adjustment of therapy.

Continuous observation of hemodynamic status is important as well. Although iNO is selective for the pulmonary circulation, changes in pulmonary blood flow can influence cardiac function, particularly in patients with underlying heart disease.

Adverse Effects and Complications

Nitrogen Dioxide Toxicity

One of the primary risks associated with inhaled nitric oxide therapy is the formation of nitrogen dioxide. This occurs when nitric oxide reacts with oxygen in the ventilator circuit. Nitrogen dioxide is a toxic gas that can cause airway inflammation and lung injury.

High levels of nitrogen dioxide may lead to pulmonary edema, cellular damage, and impaired gas exchange. Continuous monitoring of nitrogen dioxide concentrations is essential to prevent these complications.

Methemoglobinemia

Methemoglobinemia is another important adverse effect of iNO therapy. It occurs when nitric oxide oxidizes hemoglobin, converting it into a form that cannot effectively carry oxygen.

Elevated methemoglobin levels reduce the oxygen-carrying capacity of blood and can worsen hypoxemia. This is particularly concerning in neonates, who are already vulnerable to oxygenation problems.

Routine measurement of methemoglobin levels allows clinicians to detect this complication early and adjust therapy accordingly. Treatment may involve reducing the dose of nitric oxide or discontinuing therapy if levels become significantly elevated.

Rebound Pulmonary Hypertension

Rebound pulmonary hypertension is a serious complication that can occur when inhaled nitric oxide is discontinued abruptly. During therapy, endogenous nitric oxide production may be suppressed. Sudden withdrawal can lead to a rapid increase in pulmonary vascular resistance and worsening hypoxemia.

This highlights the importance of gradual weaning. By tapering the dose slowly, clinicians allow the pulmonary circulation to adapt and reduce the risk of rebound effects.

Variable Response

Not all patients respond to inhaled nitric oxide therapy. Some may show minimal improvement in oxygenation, while others may experience paradoxical worsening. Identifying responders early is important to avoid unnecessary exposure and cost.

In cases where there is no significant improvement, alternative therapies should be considered.

Weaning and Discontinuation

Weaning from inhaled nitric oxide is a critical phase of therapy that requires careful planning and close monitoring. Abrupt discontinuation can result in rebound pulmonary hypertension, a potentially life-threatening complication characterized by a rapid increase in pulmonary vascular resistance and worsening hypoxemia.

This phenomenon occurs because endogenous nitric oxide production may be suppressed during therapy. When iNO is suddenly withdrawn, the pulmonary vasculature may constrict due to the absence of both exogenous and endogenous nitric oxide activity. As a result, pulmonary pressures rise quickly, leading to decreased oxygenation.

To prevent this, iNO should be tapered gradually in a stepwise manner. A common approach involves reducing the dose by approximately 50 percent at each step. For example, the dose may be decreased from 20 ppm to 10 ppm, then to 5 ppm, and finally to 1 ppm before discontinuation. Each reduction should be accompanied by careful assessment of the patient’s oxygenation status and overall clinical stability.

During the weaning process, clinicians often increase the fraction of inspired oxygen temporarily to support oxygenation. If the patient shows signs of deterioration, such as worsening hypoxemia or hemodynamic instability, the dose may need to be increased back to the previous effective level before attempting another weaning trial.

Note: Successful discontinuation of iNO requires a stable clinical condition, adequate oxygenation on minimal support, and evidence that pulmonary vascular resistance has improved. The process should be individualized based on patient response and underlying disease.

Clinical Outcomes and Effectiveness

The primary clinical benefit of inhaled nitric oxide is the improvement of oxygenation in patients with hypoxemic respiratory failure. This effect is most pronounced in neonates with persistent pulmonary hypertension, where iNO has been shown to reduce pulmonary vascular resistance and improve ventilation-perfusion matching.

In this population, iNO has also been associated with a decreased need for extracorporeal membrane oxygenation. By improving oxygenation early in the course of illness, it can reduce the severity of hypoxemia and potentially avoid the need for more invasive and resource-intensive therapies.

However, it is important to distinguish between short-term physiological improvements and long-term clinical outcomes. While iNO often leads to rapid improvement in oxygenation, its effect on survival and long-term outcomes is less clear in many patient populations.

In conditions such as acute respiratory distress syndrome, improvements in oxygenation do not consistently translate into reduced mortality. This highlights the importance of using iNO as part of a comprehensive treatment strategy rather than as a standalone solution.

Special Considerations in Neonatal Care

Neonates represent the primary population in which inhaled nitric oxide is used. In these patients, careful attention must be given to developmental physiology and the unique characteristics of the neonatal pulmonary circulation.

The transition from fetal to postnatal circulation involves a significant decrease in pulmonary vascular resistance and an increase in pulmonary blood flow. In conditions such as persistent pulmonary hypertension of the newborn, this transition is impaired, resulting in sustained high resistance and right-to-left shunting.

iNO supports this transition by promoting vasodilation in the pulmonary circulation and encouraging blood flow through the lungs. This helps improve oxygenation and supports normal postnatal adaptation.

Because neonates are particularly sensitive to changes in oxygenation and hemodynamics, therapy must be carefully titrated and monitored. Even small changes in dose or delivery can have significant clinical effects.

In addition, neonates are more susceptible to complications such as methemoglobinemia. Their immature enzyme systems may limit their ability to reduce methemoglobin back to functional hemoglobin. This underscores the importance of regular monitoring and prompt intervention when abnormalities are detected.

Use in Other Clinical Conditions

Although inhaled nitric oxide is most commonly used in neonatal care, it has been studied in a range of other clinical conditions. These include pediatric and adult patients with pulmonary hypertension, acute respiratory distress syndrome, and postoperative complications following cardiac surgery.

In pediatric patients, iNO may be used to manage pulmonary hypertension associated with congenital heart disease or to improve oxygenation in severe respiratory failure. Its selective pulmonary effects can be particularly useful in patients with complex cardiopulmonary interactions.

In adults, inhaled nitric oxide has been used as a rescue therapy in cases of severe hypoxemia. While it can improve oxygenation temporarily, its impact on survival has not been consistently demonstrated. As a result, its use in adult populations is generally limited to specific situations or clinical trials.

iNO has also been used during diagnostic procedures to assess pulmonary vascular reactivity. By observing the response to nitric oxide, clinicians can determine whether pulmonary hypertension is reversible and guide treatment decisions.

Cost and Resource Considerations

Inhaled nitric oxide is a resource-intensive therapy that requires specialized equipment, trained personnel, and continuous monitoring. These factors contribute to its high cost, which can be a significant consideration in clinical decision-making.

In neonatal populations with persistent pulmonary hypertension, the use of iNO is often justified by its ability to reduce the need for extracorporeal membrane oxygenation. This can offset some of the associated costs by avoiding more invasive and expensive interventions.

However, in other populations where the benefits are less clear, the cost-effectiveness of iNO may be more difficult to justify. Clinicians must weigh the potential benefits against the financial and resource implications of therapy.

Careful patient selection is essential to ensure that iNO is used appropriately and effectively. This involves identifying patients who are most likely to benefit from therapy and avoiding unnecessary use in those who are unlikely to respond.

Integration with Mechanical Ventilation

Inhaled nitric oxide is typically used in conjunction with mechanical ventilation, which plays a critical role in optimizing its effectiveness. Proper ventilator management ensures adequate delivery of nitric oxide to the alveoli and supports overall respiratory function.

Ventilator settings should be adjusted to promote lung recruitment and maintain adequate ventilation. Strategies such as appropriate positive end-expiratory pressure can help improve alveolar ventilation and enhance the distribution of inhaled nitric oxide.

The interaction between ventilator settings and iNO therapy highlights the importance of a coordinated approach to respiratory care. Both therapies must be carefully managed to achieve optimal outcomes.

Note: In some cases, adjustments to ventilator settings may be required during iNO therapy to maximize its benefits. This may include changes in oxygen concentration, tidal volume, or pressure settings based on the patient’s response.

Safety and Best Practices

The safe use of inhaled nitric oxide requires adherence to established protocols and best practices. This includes proper setup and calibration of equipment, continuous monitoring of gas concentrations, and regular assessment of patient response.

Clinicians must be trained in the use of iNO delivery systems and familiar with potential complications. Early recognition of adverse effects is essential to prevent serious outcomes.

Standardized protocols can help ensure consistency in care and reduce the risk of errors. These protocols typically include guidelines for initiation, monitoring, weaning, and discontinuation of therapy.

Note: Interdisciplinary collaboration is also important. Respiratory therapists, physicians, and nursing staff must work together to manage therapy effectively and respond to changes in patient condition.

Key Points for Exams

Inhaled nitric oxide is a high-yield topic for respiratory therapy examinations. Several key concepts are frequently tested and should be well understood:

• The primary indication for iNO is persistent pulmonary hypertension of the newborn in term or near-term infants. The typical starting dose is 20 parts per million, and therapy should be titrated based on patient response.
• Monitoring requirements include measurement of nitric oxide, nitrogen dioxide, fraction of inspired oxygen, and methemoglobin levels. These parameters are essential for ensuring both safety and effectiveness.
• Common complications include nitrogen dioxide toxicity, methemoglobinemia, and rebound pulmonary hypertension. Understanding these risks and how to prevent them is critical.
• Weaning should be performed gradually to avoid rebound effects. Abrupt discontinuation is contraindicated due to the risk of rapid clinical deterioration.
• In adult patients, iNO may improve oxygenation but does not consistently improve survival and is not approved for routine use.

Inhaled Nitric Oxide Practice Questions

1. What is inhaled nitric oxide (iNO) primarily used for?
To improve oxygenation by selectively dilating pulmonary vessels.

2. How does inhaled nitric oxide improve oxygenation?
By increasing blood flow to well-ventilated alveoli and improving V/Q matching.

3. What type of vasodilator is inhaled nitric oxide?
A selective pulmonary vasodilator.

4. What is the primary neonatal indication for iNO therapy?
Persistent pulmonary hypertension of the newborn (PPHN).

5. What happens to pulmonary vascular resistance with iNO?
It decreases.

6. Why does iNO not cause systemic hypotension?
Because it is rapidly inactivated by hemoglobin in the bloodstream.

7. What enzyme does nitric oxide activate in smooth muscle cells?
Guanylate cyclase

8. What second messenger is increased by nitric oxide activity?
Cyclic guanosine monophosphate (cGMP).

9. What is the typical starting dose of iNO in neonates?
20 parts per million (ppm).

10. What is a key benefit of iNO over systemic vasodilators?
It does not significantly affect systemic vascular resistance.

11. What happens to nitric oxide after it enters the bloodstream?
It binds to hemoglobin and becomes inactivated.

12. What effect does iNO have on intrapulmonary shunting?
It reduces shunting.

13. What is a major contributor to hypoxemia that iNO helps correct?
Ventilation-perfusion mismatch

14. What type of patients are most likely to receive iNO therapy?
Term or near-term neonates with hypoxic respiratory failure.

15. What fetal structures allow right-to-left shunting in PPHN?
The foramen ovale and ductus arteriosus.

16. What is one major goal of iNO therapy in neonates?
To promote the transition to normal postnatal circulation.

17. What toxic gas can form when nitric oxide reacts with oxygen?
Nitrogen dioxide (NO₂)

18. What complication results from elevated NO₂ levels?
Airway inflammation and lung injury.

19. What is methemoglobinemia?
A condition where hemoglobin is oxidized and cannot carry oxygen effectively.

20. Why is methemoglobinemia dangerous?
It reduces oxygen delivery to tissues.

21. What parameter must be monitored to detect methemoglobinemia?
Methemoglobin levels

22. What is rebound pulmonary hypertension?
A sudden increase in pulmonary vascular resistance after stopping iNO.

23. What causes rebound pulmonary hypertension?
Abrupt discontinuation of iNO and suppressed endogenous nitric oxide production.

24. How should iNO be discontinued to avoid complications?
Gradually tapered in a stepwise manner.

25. What is one major benefit of iNO in neonatal care?
It can reduce the need for extracorporeal membrane oxygenation (ECMO).

26. What is the primary site of action for inhaled nitric oxide?
The pulmonary vasculature near ventilated alveoli.

27. How does iNO affect systemic vascular resistance?
It has minimal to no effect.

28. What is the main physiological effect of cGMP in smooth muscle?
It causes relaxation and vasodilation.

29. Why does iNO improve ventilation-perfusion matching?
Because it directs blood flow to well-ventilated lung regions.

30. What type of respiratory failure is iNO most commonly used to treat?
Hypoxemic respiratory failure

31. What is the oxygenation index often used to assess iNO initiation?
A value greater than 25.

32. What delivery system is most commonly used for iNO?
A mechanical ventilator.

33. What is required to safely administer iNO?
Specialized delivery and monitoring equipment.

34. What gas concentration must be continuously monitored during iNO therapy?
Nitric oxide concentration

35. What additional toxic byproduct must be monitored during therapy?
Nitrogen dioxide (NO₂)

36. What happens if NO₂ levels become elevated?
It can cause lung injury and inflammation.

37. What is the role of hemoglobin in iNO therapy?
It rapidly inactivates nitric oxide.

38. What is one sign that a patient is responding to iNO?
Improved arterial oxygenation.

39. What is one possible response if iNO is ineffective?
No improvement or worsening oxygenation.

40. What is a paradoxical response to iNO?
A worsening of oxygenation after administration.

41. Why should high doses of iNO be avoided?
They increase toxicity risk without added benefit.

42. What range of doses may be used depending on response?
Approximately 2 to 80 ppm.

43. What is the primary goal when titrating iNO?
To achieve optimal oxygenation with the lowest effective dose.

44. What happens to pulmonary artery pressure with iNO?
It decreases.

45. What role does iNO play in pulmonary blood flow?
It increases flow to ventilated alveoli.

46. What condition involves failure of pulmonary vascular resistance to decrease after birth?
Persistent pulmonary hypertension of the newborn (PPHN)

47. What is one diagnostic use of iNO?
Assessing pulmonary vascular responsiveness.

48. What happens to oxygen delivery when methemoglobin levels rise?
It decreases.

49. What is a key monitoring parameter alongside NO and NO₂?
Fraction of inspired oxygen (FiO₂)

50. What type of therapy is iNO considered in critical care?
A targeted pulmonary therapy.

51. What type of smooth muscle does iNO primarily affect?
Pulmonary vascular smooth muscle.

52. Through what membrane does nitric oxide diffuse to reach vessels?
The alveolar-capillary membrane.

53. What happens to blood flow distribution after iNO administration?
It is redirected toward ventilated lung regions.

54. What is the main benefit of selective vasodilation in the lungs?
Improved gas exchange efficiency.

55. What condition results in right-to-left shunting in neonates?
Persistent pulmonary hypertension of the newborn.

56. What is a key goal of iNO therapy in hypoxemia?
To increase arterial oxygen levels.

57. What clinical tool confirms pulmonary hypertension in neonates?
Echocardiography

58. What is the effect of iNO on poorly ventilated alveoli?
Minimal to no vasodilation occurs.

59. Why is selective delivery of iNO important?
It prevents unnecessary blood flow to nonfunctional lung areas.

60. What type of lung regions receive the most benefit from iNO?
Well-ventilated alveolar regions.

61. What is one advantage of iNO’s rapid onset?
Quick improvement in oxygenation.

62. What is one limitation of iNO in non-neonatal patients?
Lack of proven survival benefit.

63. What type of shunt is reduced with iNO therapy?
Intrapulmonary right-to-left shunt.

64. What happens to oxygenation when V/Q matching improves?
It increases.

65. What clinical parameter reflects improved oxygenation?
Arterial oxygen tension (PaO₂)

66. What happens if pulmonary vascular resistance remains high?
Oxygenation is impaired.

67. What type of monitoring device detects NO₂ levels?
A gas analyzer.

68. What must be calibrated regularly in iNO therapy?
Delivery and monitoring equipment.

69. What role do alarm systems play in iNO delivery?
They alert clinicians to unsafe gas levels.

70. What clinical sign may indicate worsening pulmonary hypertension?
Decreasing oxygen saturation

71. What adjustment may be made during iNO weaning to support oxygenation?
Increasing FiO₂

72. What is one risk of excessive nitric oxide exposure?
Increased methemoglobin formation.

73. What type of molecule is nitric oxide classified as?
A gaseous signaling molecule.

74. What is required for safe iNO administration in clinical settings?
Trained personnel

75. What is a key reason for careful patient selection with iNO?
Not all patients respond to therapy.

76. What type of circulation does iNO primarily target?
The pulmonary circulation.

77. What is the effect of iNO on pulmonary artery pressure?
It lowers pulmonary artery pressure.

78. What happens to blood flow in collapsed alveoli during iNO therapy?
It remains reduced due to lack of ventilation.

79. What condition may show only temporary improvement with iNO?
Acute respiratory distress syndrome.

80. What is one reason iNO is considered a localized therapy?
It acts only in ventilated areas of the lungs.

81. What is the effect of iNO on cardiac output in most patients?
It generally has minimal direct effect.

82. What type of gas delivery requires precise blending for iNO therapy?
Medical gas mixtures delivered through ventilators.

83. What is the primary purpose of gas analyzers in iNO systems?
To measure and verify gas concentrations.

84. What may occur if iNO delivery is interrupted suddenly?
Rapid worsening of oxygenation.

85. What is a key sign that iNO therapy may need adjustment?
Changes in oxygenation or hemodynamic instability.

86. What happens to endogenous nitric oxide production during prolonged therapy?
It may become suppressed.

87. What is the purpose of stepwise dose reduction during weaning?
To allow gradual adaptation of pulmonary vessels.

88. What is the final low dose often reached before discontinuation?
Approximately 1 ppm

89. What is one potential cardiovascular effect of increased pulmonary blood flow?
Increased left ventricular filling pressure.

90. What patient population benefits most from iNO therapy?
Term and near-term neonates with PPHN.

91. What condition may require reassessment if there is no response to iNO?
Underlying cause of hypoxemia.

92. What type of therapy is iNO considered in terms of precision medicine?
Targeted therapy

93. What clinical feature may indicate significant right-to-left shunting?
Preductal and postductal oxygen saturation differences.

94. What is one benefit of early iNO use in severe hypoxemia?
Reduced need for ECMO.

95. What happens when nitric oxide reacts with oxygen in excess amounts?
Formation of nitrogen dioxide.

96. What is one reason neonates are at higher risk for methemoglobinemia?
Immature enzymatic systems.

97. What is the purpose of monitoring ventilator settings during iNO therapy?
To ensure effective gas delivery and oxygenation.

98. What is one indication that pulmonary vascular resistance is decreasing?
Improved oxygenation

99. What type of response indicates effective iNO therapy?
Improved PaO₂ and oxygen saturation.

100. What is the ultimate goal of iNO therapy in respiratory care?
To improve oxygenation while minimizing systemic effects.

Final Thoughts

Inhaled nitric oxide (iNO) is a targeted therapy that plays a vital role in the management of neonatal hypoxemic respiratory failure, particularly in persistent pulmonary hypertension of the newborn. Its ability to selectively reduce pulmonary vascular resistance and improve ventilation-perfusion matching allows for meaningful improvements in oxygenation without compromising systemic hemodynamics.

Despite these benefits, its use requires careful monitoring, appropriate dosing, and a structured weaning process to avoid complications.

When applied correctly and in the right clinical context, iNO remains an important tool in respiratory care, supporting improved patient outcomes through precise and localized therapeutic action.